Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100965258 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2164 (Electronic) Linking ISSN: 14712164 NLM ISO Abbreviation: BMC Genomics Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2000-
    • Subject Terms:
      Phylogeny*; High-Throughput Screening Assays/*methods ; Influenza A virus/*genetics ; Viral Matrix Proteins/*genetics; Amino Acid Substitution ; Epistasis, Genetic ; Humans ; Influenza A virus/pathogenicity ; Sequence Deletion/genetics
    • Abstract:
      Background: Epistasis is one of the central themes in viral evolution due to its importance in drug resistance, immune escape, and interspecies transmission. However, there is a lack of experimental approach to systematically probe for epistatic residues.
      Results: By utilizing the information from natural occurring sequences and high-throughput genetics, this study established a novel strategy to identify epistatic residues. The rationale is that a substitution that is deleterious in one strain may be prevalent in nature due to the presence of a naturally occurring compensatory substitution. Here, high-throughput genetics was applied to influenza A virus M segment to systematically identify deleterious substitutions. Comparison with natural sequence variation showed that a deleterious substitution M1 Q214H was prevalent in circulating strains. A coevolution analysis was then performed and indicated that M1 residues 121, 207, 209, and 214 naturally coevolved as a group. Subsequently, we experimentally validated that M1 A209T was a compensatory substitution for M1 Q214H.
      Conclusions: This work provided a proof-of-concept to identify epistatic residues by coupling high-throughput genetics with phylogenetic information. In particular, we were able to identify an epistatic interaction between M1 substitutions A209T and Q214H. This analytic strategy can potentially be adapted to study any protein of interest, provided that the information on natural sequence variants is available.
    • References:
      Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15993-8. (PMID: 25355911)
      Mol Ther. 2014 Jan;22(1):233-8. (PMID: 23831594)
      J Gen Virol. 1994 Apr;75 ( Pt 4):945-8. (PMID: 8151308)
      J Virol. 2008 Jan;82(2):596-601. (PMID: 17942553)
      Mol Biol Evol. 2015 Nov;32(11):2944-60. (PMID: 26226986)
      J Mol Evol. 2010 Jan;70(1):98-105. (PMID: 20041240)
      Retrovirology. 2014;11:124. (PMID: 25522661)
      Science. 2010 Jun 4;328(5983):1272-5. (PMID: 20522774)
      Clin Exp Vaccine Res. 2014 Jan;3(1):12-28. (PMID: 24427759)
      Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19872-7. (PMID: 24243955)
      J Gen Virol. 1979 Jan;42(1):73-88. (PMID: 759560)
      PLoS Genet. 2014 May;10(5):e1004328. (PMID: 24811236)
      Genetics. 2006 May;173(1):9-23. (PMID: 16547113)
      J Virol. 2009 May;83(9):4153-62. (PMID: 19225007)
      PLoS One. 2013;8(11):e80635. (PMID: 24278298)
      Elife. 2013;2:e00631. (PMID: 23682315)
      Nat Methods. 2014 Aug;11(8):801-7. (PMID: 25075907)
      Mini Rev Med Chem. 2014;14(10):819-30. (PMID: 25342196)
      PLoS Genet. 2010 Oct;6(10):e1001162. (PMID: 20975933)
      PLoS One. 2010;5(1):e8591. (PMID: 20066038)
      Nat Commun. 2015;6:7491. (PMID: 26082035)
      Virology. 2001 Jan 20;279(2):439-46. (PMID: 11162800)
      Biopolymers. 1983 Dec;22(12):2577-637. (PMID: 6667333)
      J Infect Dis. 2011 Jan 1;203(1):6-10. (PMID: 21148489)
      J Biol Chem. 2002 Oct 18;277(42):39880-6. (PMID: 12183461)
      Proc Natl Acad Sci U S A. 2007 May 8;104(19):7999-8004. (PMID: 17468399)
      Curr Top Microbiol Immunol. 1992;176:119-30. (PMID: 1600749)
      AIDS Rev. 2003 Jan-Mar;5(1):52-61. (PMID: 12875108)
      J Virol. 2008 Dec;82(23):11869-79. (PMID: 18815307)
      Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11301-6. (PMID: 9326604)
      Virology. 1998 Jan 5;240(1):127-37. (PMID: 9448697)
      Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7827-30. (PMID: 10393906)
      Influenza Other Respir Viruses. 2013 Dec;7 Suppl 4:81-9. (PMID: 24224823)
      Bioinformatics. 2006 Nov 15;22(22):2821-2. (PMID: 17005535)
      PLoS One. 2012;7(11):e50595. (PMID: 23209789)
      Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15376-9. (PMID: 15492220)
      J Virol. 2009 Sep;83(17):8655-61. (PMID: 19553312)
      PLoS Genet. 2015 Jul;11(7):e1005310. (PMID: 26132554)
      Genetics. 2005 Jul;170(3):1001-8. (PMID: 15879507)
      AIDS. 1999 Dec 3;13(17):2349-59. (PMID: 10597776)
      J Virol. 1997 Sep;71(9):6662-70. (PMID: 9261388)
      Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:58-62. (PMID: 23279898)
      Cell. 1992 May 1;69(3):517-28. (PMID: 1374685)
      Virus Res. 2004 Dec;106(2):147-65. (PMID: 15567494)
      Acta Virol. 2000 Oct;44(5):241-8. (PMID: 11252668)
      J Virol. 2008 Sep;82(18):9283-7. (PMID: 18614638)
      J Virol. 2000 Dec;74(24):11538-47. (PMID: 11090151)
      Nature. 2008 Jan 31;451(7178):591-5. (PMID: 18235503)
      J Exp Med. 2001 Feb 5;193(3):375-86. (PMID: 11157057)
      PLoS One. 2012;7(5):e36546. (PMID: 22590562)
      Influenza Other Respir Viruses. 2012 Nov;6(6):404-16. (PMID: 22260278)
      PLoS Genet. 2009 Jul;5(7):e1000578. (PMID: 19629166)
      Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50. (PMID: 10430945)
      PLoS Genet. 2011 Feb;7(2):e1001301. (PMID: 21390205)
      Sci Rep. 2014;4:4942. (PMID: 24820965)
      Elife. 2014;3. doi: 10.7554/eLife.03300. (PMID: 25006036)
      Curr Opin Genet Dev. 2013 Dec;23(6):700-7. (PMID: 24290990)
      J Biol Chem. 2005 Jun 3;280(22):21463-72. (PMID: 15784624)
      FEBS J. 2011 Dec;278(24):4905-16. (PMID: 21985378)
      Mol Biol Evol. 2014 Aug;31(8):1956-78. (PMID: 24859245)
      Biophys J. 1995 Oct;69(4):1363-71. (PMID: 8534806)
      J Virol. 2013 Jan;87(2):1193-9. (PMID: 23152521)
      Bioinformatics. 2005 Feb 1;21(3):379-84. (PMID: 15377502)
      PLoS Pathog. 2014 Apr;10(4):e1004064. (PMID: 24722365)
      Nature. 2013 Aug 29;500(7464):571-4. (PMID: 23873039)
      Biochemistry. 2001 May 22;40(20):6053-60. (PMID: 11352741)
      J Virol. 2014 Sep 1;88(17):10157-64. (PMID: 24965464)
      PLoS Genet. 2015 Feb;11(2):e1004918. (PMID: 25671604)
      Nat Rev Genet. 2013 Apr;14(4):249-61. (PMID: 23458856)
      Curr Biol. 2014 Nov 17;24(22):2643-51. (PMID: 25455030)
    • Grant Information:
      R21 AI110261 United States AI NIAID NIH HHS; R21-AI-110261 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Viral Matrix Proteins)
    • Publication Date:
      Date Created: 20160113 Date Completed: 20160928 Latest Revision: 20181113
    • Publication Date:
      20240829
    • Accession Number:
      PMC4710013
    • Accession Number:
      10.1186/s12864-015-2358-7
    • Accession Number:
      26754751